Exscientia announces multi-target, AI-driven drug discovery collaboration with Bristol Myers Squibb
Upfront and potential milestones of over $1.2bn in addition to tiered royalties OXFORD, England–(BUSINESS WIRE)– Exscientia, the clinical stage, Artificial Intelligence (AI)-driven pharmatech company, announced...